Financial Contrast: Shuttle Pharmaceuticals (NASDAQ:SHPH) and Daiichi Sankyo (OTCMKTS:DSNKY)

Daiichi Sankyo (OTCMKTS:DSNKY) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Insider & Institutional Ownership

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Daiichi Sankyo and Shuttle Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daiichi Sankyo	0	1	0	0	2.00
Shuttle Pharmaceuticals	1	0	0	0	1.00

Profitability

This table compares Daiichi Sankyo and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daiichi Sankyo	12.32%	15.75%	6.91%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Risk and Volatility

Daiichi Sankyo has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Valuation and Earnings

This table compares Daiichi Sankyo and Shuttle Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daiichi Sankyo	$14.10 billion	2.30	$1.72 billion	$0.94	18.49
Shuttle Pharmaceuticals	N/A	N/A	-$11.72 million	($47.70)	-0.07

Daiichi Sankyo has higher revenue and earnings than Shuttle Pharmaceuticals. Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Daiichi Sankyo, indicating that it is currently the more affordable of the two stocks.

Summary

Daiichi Sankyo beats Shuttle Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.